Loading...
NPI 1679650949 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Imran Ahmed is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 87 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Imran Ahmed |
| Address | 100 N City Pkwy Ste 160 |
| City | Las Vegas |
| State | NV |
| ZIP | 89106 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | November 1, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4M |
| Medicaid | $7.6K |
This provider is a Medicare-scale oncology practice: total Medicare revenue is $4M while total Medicaid revenue is $7.6K, so the provider is effectively Medicare-dominant in scale and not a major Medicaid revenue participant. The two-payer mix shows Medicare driving virtually all billed dollars and Medicaid representing a de minimis share of this provider’s lifetime revenue.
Revenue concentration on Medicare is high and narrowly focused: the precomputed top three Medicare codes account for 59.4% of Medicare revenue, driven by J9271, J9144, and 78815. Those three codes (pembrolizumab, daratumumab with hyaluronidase, and PET/CT imaging) together constitute the bulk of billed Medicare oncology services for this provider.
Medicaid billing is essentially single-code: the precomputed top-3 Medicaid share is 100.0%, and all reported Medicaid revenue ($7.6K) is from 99214. In other words, Medicaid activity is limited to office E/M visits and does not reflect the infusion-, imaging-, or biologics-driven revenue mix seen in Medicare.
The code mix and descriptions point to an infusion-centric hematology/oncology operation: high-revenue Medicare items include J9271 (pembrolizumab) and J9144 (daratumumab with hyaluronidase), plus imaging code 78815 (PET/CT). Together these codes indicate the practice provides high-cost immunotherapy and monoclonal-antibody infusions supported by advanced oncologic imaging on the Medicare population.
Competitive standing is mixed by code: J9144 ranks #43 of 615 nationally (93th percentile) and is labeled notably above typical national volume, signaling an above-average national presence for daratumumab administration. By contrast, J9271 ranks #192 of 1841 (90th percentile) for pembrolizumab and 78815 ranks #522 of 6566 (92th percentile) — both described as typical or unremarkable volume despite high percentiles, so the practice appears especially strong for certain drugs but not uniformly dominant across all top oncology items.
Beyond the top three, multiple infusion and supportive-care codes are reported at high national percentiles (for example J0897 at the 97th percentile, J1568 at the 93th percentile, and 96375 at the 98th percentile), which reinforces that the provider operates a busy infusion/service line for oncology therapeutic administration and related care. These notable volumes for infusion-related codes support the interpretation of an active outpatient infusion suite.
The provider’s office evaluation-and-management activity differs by payer: Medicare shows 99214 as a material contributor (1K claims, $89 avg paid/claim, $90.5K revenue and a national rank of #10968 of 479517 at the 98th percentile, described as notably above typical), whereas Medicaid’s entire $7.6K is also 99214 but ranks #1650 of 2254 in-state at the 26th percentile (typical, unremarkable). This contrast indicates substantial Medicare E/M visit volume but only limited Medicaid E/M engagement within the state.
Tenure is long-standing: the NPI was enumerated 2006-11-01 (~20 years ago), indicating the provider has an established billing history and a multi-year presence in the Medicare program that aligns with the accumulated $4M Medicare lifetime revenue and the pattern of specialty oncology services reported.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
87 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 26,400 | $40 | $1.1M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 21,420 | $30 | $706.9K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 320 | $1,250 | $404.4K |
| J0897 | Injection, denosumab, 1 mg | 18,720 | $20 | $337K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 10,160 | $30 | $325.1K |
| J9299 | Injection, nivolumab, 1 mg | 8,200 | $20 | $180.4K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 350 | $280 | $96.6K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 47,020 | $1 | $94K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,020 | $90 | $90.5K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 780 | $90 | $71.8K |
Showing 1–10 of 87
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
87 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 2 | 40 | 13,000 | $40 | $625.8K |
| J9144 | 2 | 10 | 9,180 | $40 | $445.4K |
| J9299 | 9 | 10 | 14,400 | $20 | $362K |
| J1568 | 2 | 10 | 4,470 | $30 | $164.2K |
| J0897 | 3 | 70 | 3,630 | $20 | $94.6K |
| 78815 | 2 | 60 | 60 | $930 | $80.4K |
| J0881 | 3 | 30 | 17,400 | $1 | $49.5K |
| Q5122 | 1 | 10 | 350 | $90 | $37.7K |
| J1439 | 7 | 10 | 24,000 | $1 | $27.7K |
| 99233 | 623 | 1,150 | 150 | $90 | $26.8K |
Showing 1–10 of 87
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 80 | $90 | $7.6K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,650 | 2,250 | 290 | $60 | $138K |
Other providers in the same ZIP code as Imran Ahmed, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.